Urologic Oncology: Seminars and Original Investigations
Seminars article25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology
Introduction
25 years ago, prostate cancer that had spread to pelvic lymph nodes was considered terminal, radiation therapy was delivered with 3D-conformal technique [1], and the role of PSA had not been fully clarified. Androgen deprivation frequently consisted of bilateral orchiectomy, and “hormone resistant,” prostate cancer patients had a median survival less than 6 months with few systemic treatment options, primarily mitoxantrone [2]. Today multimodal therapy achieves cure in many locally advanced prostate cancer patients, and men whose cancer has progressed to the metastatic castration-resistant state have a median survival of more than 30 months with multiple lines of systemic therapy known to prolong life. Major changes in the field of prostate cancer over the last 25 years related to understanding of risk factors, improved diagnostic, and prognostic tools, more effective local and systemic therapy, and preserving quality of life will be summarized in this review.
Section snippets
Epidemiology
From 1995 to 2000 prostate cancer incidence rose while death rates declined, primarily attributed to the introduction of prostate specific antigen (PSA) screening. Incidence subsequently dropped by about 2.4% per year and although deaths from prostate cancer remain above 30,000 per year in the United States [3], the death rate for prostate cancer has dropped 52% from 1993 to 2017. Strikingly, the death rate for African American men remain more than double that for White men from 1995 [4] to the
Screening and diagnosis
While PSA for screening was widely adopted in the late 1980’s, it took many years for randomized, level 1 evidence to prove survival benefit, yet prostate cancer screening remains controversial to this day [9,10]. Limitations and hazards of PSA testing were recognized, leading to the Unites States Preventative Services Task Force (USPSTF) recommendation against prostate cancer screening for all men in 2012 due to a consensus that the risks from PSA screening outweighed any survival benefits [11]
Advances in treatment of localized prostate cancer
The initial response to what appeared to be an epidemic of prostate cancer after widespread PSA screening was introduced was very high treatment rates of localized disease across the board [16]. A critical insight for both diagnosis and evaluation of prostate cancer in the last 25 years was the realization that prostate cancer biology is extremely heterogenous and treatment should be based on careful risk stratification with consideration of costs as well as potential therapeutic side effects [
Advances in radiation therapy for prostate cancer
Radiation treatment techniques have changed significantly over the last 25 years benefiting from advances in technology [26]. Intensity-modulated radiation therapy, adopted in the 2000, and proton radiation therapy deliver less radiation dose to the bowel and bladder than older 3D-based treatment techniques with the goal of reducing bowel and urinary side effects of external beam radiation treatment. More conformal radiation techniques and improvements in accuracy of daily treatment alignment
Advanced disease: Castration therapy and beyond
In 1994, the hormonal treatment of prostate cancer had not progressed dramatically since the landmark work of Charles Huggins in the 1940; trans-scrotal bilateral orchiectomy was still widely used. The alternative to surgical castration was to manipulate the pituitary-gonadal axis via luteinizing hormone releasing hormone(LHRH), which had been discovered by Andrew Schally. Analogs of LHRH were developed; these caused a transient increase in testosterone production which resulted in a “flare,”
Survivorship and future directions
Much of the work in the field of definitive management of localized prostate cancer is driven by the goal of balancing treatment benefits with related quality of life harms. Foundational to the understanding of this risk/benefit calculus has been the work in developing validated prostate cancer-specific patient reported outcomes [[65], [66], [67]]. Using these instruments to prospectively compare effectiveness has shed light on the likely course of recovery and long-term side-effects of various
Conclusion
Tremendous progress has been made in the management of prostate cancer over the last 25 years. Major studies have clarified the impact of screening on prostate cancer diagnosis and mortality and molecular tools have led to risk stratification for management of early disease, while the wealth of randomized clinical trials across the spectrum of prostate cancer have yielded landscape-changing therapeutics to extend overall survival, importantly balancing cancer control with quality of life.
References (81)
- et al.
Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium
Lancet
(1994) - et al.
Targeted prostate cancer screening in BRCA1 and BRCA2 carriers: results from the initial screening round of the IMPACT study
Eur Urol
(2014) - et al.
A 16-yr Follow-up of the european randomized study of screening for prostate cancer
Eur Urol
(2019) - et al.
Genomic markers in prostate cancer decision making
Eur Urol
(2018) - et al.
The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry
J Urol
(2004) - et al.
Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE)
J Urol
(2003) - et al.
Active surveillance for prostate cancer: a systematic review of the literature
Eur Urol
(2012) - et al.
Technique of da Vinci robot-assisted anatomic radical prostatectomy
Urology
(2002) - et al.
Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database
Eur Urol
(2016) - et al.
Androgen suppression combined with elective nodal and dose-escalated radiation therapy (the ASCENDE-RT trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer
Int J Rad Oncol Biol Phys
(2017)
“Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.”
Lancet Oncol
Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies
Int J Radiat Oncol Biol Phys
20 years of progress in radiation oncology: prostate cancer
Semin Radiat Oncol
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial
Lancet Oncol.
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III
Trial.Eur Urol
Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31
Int J Radiat Oncol Biol Phys
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial
Lancet
Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer
Urology
Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument
Urology
AUA white paper on implementation of shared decision making into urological practice
Urol Pract
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomized, double-blind study
Lancet
[(177)Lu]- PSMA-617 radionuclide treatment in patients with metastatic castration resistant prostate cancer (LuPSMA trial): a single-centre, single-arm phase 2 study
Lancet Oncol
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
J Clin Oncol
Cancer statistics, 2020
CA Cancer J Clin
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control
J Natl Cancer Inst
. Cancer risks in BRCA2 mutation carriers
J Natl Cancer Inst (Bethesda)
Inherited DNA-repair gene mutations in men with metastatic prostate cancer
N Engl J Med
Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up
J Natl Cancer Inst
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement
Ann Intern Med
Screening for prostate cancer: US preventive services task force recommendation statement
JAMA
Prostate cancer incidence and survival, by stage and race/ethnicity - United States, 2001-2017
MRI-Targeted or standard biopsy for prostate-cancer diagnosis
N Engl J Med
20-year outcomes following conservative management of clinically localized prostate cancer
JAMA
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
JAMA
Active surveillance for the management of localized prostate cancer (cancer care ontario guideline): american society of clinical oncology clinical practice guideline endorsement
J Clin Oncol
Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations
Prostate
MRI-targeted or standard biopsy for prostate-cancer diagnosis
New Engl J Med
Radiation therapy modalities in prostate cancer
Review J Natl Compr Canc Netw
J Clin Oncol.
Cited by (2)
Perspectives on prostate cancer: advances and pending challenges for a multidisciplinary oncological approach in South America
2024, International Urology and NephrologyEditorial: Challenges in the prevention of prostate cancer
2023, Frontiers in Oncology